Massachusetts Pharmacists Association

02/06/2026

Women with inherited mutations in the BRCA1 or BRCA2 genes often experience early menopause because they undergo bilateral salpingo-oophorectomy at a young age. The safety of menopausal hormone therapy (MHT) in this group has long been questioned. A new study helps put those concerns to rest, suggesting no increased breast cancer risk with MHT use. https://www.uspharmacist.com/article/menopause-therapy-not-linked-to-higher-breast-cancer-risk-in-brca-carriers?wc_mid=6220:779022&wc_rid=6220:744932

02/05/2026

02/04/2026

FDA has approved Gepotidacin (Blujepa) for two conditions: uncomplicated urinary tract infections (uUTIs) in females (12+ years) and uncomplicated urogenital gonorrhea in adults and adolescents (12+ years with limited options). It's a significant approval as it's the first new class of oral antibiotics for UTIs in almost 30 years and the first for gonorrhea in over 30 years, offering new hope against resistant bacteria. https://us.gsk.com/en-us/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-as-oral-option-for-treatment-of-uncomplicated-urogenital-gonorrhea-ugc/

02/03/2026

Artificial intelligence for improving decision-making in bacterial infection management: a narrative review. https://academic.oup.com/jac/article/81/1/dkaf470/8388020?login=false

02/02/2026

Emergency preparedness resources for pharmacists
Healthcare Ready’s RxOpen Tool
https://healthcareready.org/rxopen/
HHS emPOWER Map
https://empowerprogram.hhs.gov/empowermap
Hospital Preparedness Program
https://aspr.hhs.gov/HealthCareReadiness/HPP/Pages/about-hpp.aspx
Emergency Prescription Assistance Program
https://aspr.hhs.gov/EPAP/Pages/default.aspx
PhRMA’s Medicine Assistance Tool
https://medicineassistancetool.org/
NABP, in collaboration with member boards, created an Emergency Planning Guide for boards of pharmacy
https://nabp.pharmacy/members/board-resources/
NCPA Foundation resources portfolio for independent community pharmacies regarding disaster preparedness, relief, response, and long-term recovery
www.ncpafoundation.org/disaster-resources-independent-community-pharmacy/
NCPDP emergency preparedness guidance and documents
www.ncpdp.org/resources/emergency-preparedness
Ready Business
Ready.gov/business
National Voluntary Organizations Active in Disaster
nvoad.org
NCPA webinar: “Severe Weather Preparedness for Community Pharmacies”
www.youtube.com/watch?v=GUm7EUEty8k
APhA webinar: “Disaster and Emergency Preparedness”
learn.pharmacist.com/learn/courses/4799/disaster-and-emergency-prepardness
APhA’s Disasters and Emergencies guide
Visit apha.us/EmergenciesHDBK for a timely guide to planning and practical strategies for rapidly evolving situations.

02/01/2026

Court Recognizes Student Pharmacist’s RIght to Freedom of Speech https://www.pharmacist.com/Publications/Pharmacy-Today/Article/court-recognizes-student-pharmacists-right-to-freedom-of-speech

01/31/2026

FDA approved Zoliflodacin for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg. https://www.idstewardship.com/zoliflodacin-nuzolvence/

01/29/2026

What’s the future of virtual pharmacy care post pandemic?
Pharmacy services—like everything else—changed during the COVID-19 pandemic as patients used telehealth not only for physician visits, but for whatever needs they would normally go to their local pharmacy to meet. https://www.pharmacist.com/Blogs/CEO-Blog/Article/whats-the-future-of-virtual-pharmacy-care-post-pandemic

01/27/2026

FDA has authorized a new formulation of ranitidine tablets, signaling the medication's comeback after it was pulled from the shelves five years ago. The approval was announced on November 24, 2025 following an intensive safety and manufacturing review. FDA confirmed that the new product has strict storage and handling instructions to prevent the formation of N-nitrosodimethylamine (NDMA) during the product's shelf life. https://trial.medpath.com/news/367d01a5f329629d/fda-approves-reformulated-ranitidine-after-five-year-market-absence-due-to-carcinogen-concerns